Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study

MLA

Arnaud Pigneux, et al. “Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study.” Cancers, Mar. 2020. EBSCOhost, https://doi.org/10.3390/cancers12040773.

APA

Arnaud Pigneux, Audrey Sarry, Eric Delabesse, Emilie Bérard, Harmony Leroy, Jean-Baptiste Rieu, Suzanne Tavitian, Christian Recher, Noémie Gadaud, Jean-Philippe Vial, Isabelle Luquet, François Vergez, Emilie Klein, Nicolas Lechevalier, Anne-Charlotte de Grande, Sarah Bertoli, Thibaut Leguay, Audrey Bidet, Pierre-Yves Dumas, & Laetitia Largeaud. (2020). Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers. https://doi.org/10.3390/cancers12040773

Chicago

Arnaud Pigneux, Audrey Sarry, Eric Delabesse, Emilie Bérard, Harmony Leroy, Jean-Baptiste Rieu, Suzanne Tavitian, et al. 2020. “Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia Before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study.” Cancers, March. doi:10.3390/cancers12040773.